Katsunori Ikewaki, Makoto Ayaori. Show Affiliations »
Abstract
Entities: Disease Species
Mesh： See more » Analysis of VarianceAtorvastatinBiomarkers/bloodCholesterol, LDL/bloodEvidence-Based MedicineFluorobenzenes/adverse effectsFluorobenzenes/therapeutic useHeptanoic Acids/adverse effectsHeptanoic Acids/therapeutic useHumansHydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effectsHydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic useHypercholesterolemia/bloodHypercholesterolemia/drug therapyPatient SelectionPyrimidines/adverse effectsPyrimidines/therapeutic usePyrroles/adverse effectsPyrroles/therapeutic useQuinolines/adverse effectsQuinolines/therapeutic useRosuvastatin CalciumSulfonamides/adverse effectsSulfonamides/therapeutic useTime FactorsTreatment Outcome
Substances： See more » BiomarkersCholesterol, LDLFluorobenzenesHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrimidinesPyrrolesQuinolinesSulfonamidesRosuvastatin CalciumAtorvastatinpitavastatin
Year: 2011 PMID： 21532174 DOI： 10.1253/circj.cj-11-0410
Source DB: PubMed Journal: Circ J ISSN： 1346-9843 Impact factor: 2.993